Diagnostic Potential of Preventative Whole-Body MRI Scans with Dr. John Simon SimonMed Imaging TRANSCRIPT
Release Date: 04/29/2024
Empowered Patient Podcast
Alice Lin, DCT Solutions Director in the DCT Business Department of Tigermed Consulting, a global CRO, contract research organization, that provides biopharmaceutical and medical device companies with a range of services including digital technology to conduct decentralized clinical trials. Their approach focuses on patient-centricity, efficiency, and adaptability. By utilizing digital tools such as virtual visits, wearable devices, and mobile apps, Tigermed aims to make clinical trials more accessible and convenient for patients, improving recruitment and retention rates. They also emphasize...
info_outline Deploying Technology in Decentralized Clinical Trials Improves Recruitment and Retention with Alice Lin Tigermed ConsultingEmpowered Patient Podcast
Alice Lin, DCT Solutions Director in the DCT Business Department of Tigermed Consulting, a global CRO, contract research organization, that provides biopharmaceutical and medical device companies with a range of services including digital technology to conduct decentralized clinical trials. Their approach focuses on patient-centricity, efficiency, and adaptability. By utilizing digital tools such as virtual visits, wearable devices, and mobile apps, Tigermed aims to make clinical trials more accessible and convenient for patients, improving recruitment and retention rates. They also emphasize...
info_outline Developing Drug Targeting B Cells in Autoimmune Disease of the Kidney IgA Nephropathy with Dr. Marshall Fordyce Vera Therapeutics TRANSCRIPTEmpowered Patient Podcast
Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our...
info_outline Developing Drug Targeting B Cells in Autoimmune Disease of the Kidney IgA Nephropathy with Dr. Marshall Fordyce Vera TherapeuticsEmpowered Patient Podcast
Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our...
info_outline Developing Drugs to Treat Rare Liver Diseases NASH PBC ACLF with Pascal Prigent GENFIT TRANSCRIPTEmpowered Patient Podcast
Pascal Prigent, the CEO of GENFIT, a French biotech that has been working on liver diseases for about 20 years and has developed a compound called elafibranor for conditions such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and acute-on-chronic liver failure (ACLF). He highlights the high unmet medical need in ACLF, which currently has no approved treatment options and a high mortality rate. Prigent also discusses Genfit's partnership with Ipsen for the development and commercialization of elafibranor in PBC. Pascal explains, "In reality, we don't have any...
info_outline Developing Drugs to Treat Rare Liver Diseases NASH PBC ACLF with Pascal Prigent GENFITEmpowered Patient Podcast
Pascal Prigent, the CEO of GENFIT, a French biotech that has been working on liver diseases for about 20 years and has developed a compound called elafibranor for conditions such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and acute-on-chronic liver failure (ACLF). He highlights the high unmet medical need in ACLF, which currently has no approved treatment options and a high mortality rate. Prigent also discusses Genfit's partnership with Ipsen for the development and commercialization of elafibranor in PBC. Pascal explains, "In reality, we don't have any...
info_outline Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates TRANSCRIPTEmpowered Patient Podcast
Phil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, and other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, and determine dosage and form...
info_outline Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston AssociatesEmpowered Patient Podcast
Phil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, and other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, and determine dosage and form...
info_outline Preventative and Acute Treatment for Rare Genetic Disease HAE with Salome Juethner Takeda TRANSCRIPTEmpowered Patient Podcast
Salome Juethner, Senior Medical Director, Head of Rare Genetics, and Interim Head of Rare GI at Takeda, discusses HAE, hereditary angioedema, a rare genetic disorder that causes painful and unpredictable swelling attacks that can be life-threatening. Salome emphasizes the need to educate physicians to consider HAE as a potential diagnosis in children as young as two years old and underrepresented racial and ethnic groups. To treat HAE, Takeda offers Takhzyro, a medication that can be used on-demand and as a preventative therapy, administered at home through a subcutaneous injection. ...
info_outline Preventative and Acute Treatment for Rare Genetic Disease HAE with Salome Juethner TakedaEmpowered Patient Podcast
Salome Juethner, Senior Medical Director, Head of Rare Genetics, and Interim Head of Rare GI at Takeda, discusses HAE, hereditary angioedema, a rare genetic disorder that causes painful and unpredictable swelling attacks that can be life-threatening. Salome emphasizes the need to educate physicians to consider HAE as a potential diagnosis in children as young as two years old and underrepresented racial and ethnic groups. To treat HAE, Takeda offers Takhzyro, a medication that can be used on-demand and as a preventative therapy, administered at home through a subcutaneous injection. ...
info_outlineDr. John Simon, CEO and Founder of SimonMed Imaging makes various medical imaging technologies available, including X-rays, ultrasound, MRI, and PET/CT scans, which have traditionally been used for diagnosis and tracking changes. With the SimonONE whole-body MRI scan, SimonMed offers an affordable preventative screening approach that, with the assistance of AI and advancements in imaging technology, looks for abnormalities and detects subtle changes. Ideally, MRI scans will become more routine in annual exams to catch treatable conditions sooner.
John elaborates, "About 20, 25 years ago, diagnostic imaging went from a very limited specialty within the hospital setting to an often-used technology. This great technology is used in the outpatient setting. So, I founded my first outpatient radiology office over 20 years ago, and it included some of the most advanced equipment you could obtain at that time, including cardiac CT and MRI scanners, which were incredibly fast for that time. What that technology enabled us to do was to do outpatient imaging studies very quickly, less expensively, and very accurately."
"A whole-body MRI involves a series of MRI sequences, more than one, looking at the body. Typically, we look at the head, neck, chest, abdomen, and pelvis. We do specialized sequences within those areas looking for aneurysms, looking for vascular changes in the body, looking at the health of the brain for not only excluding particularly cancers in the brain, for example, but also looking for early signs of Alzheimer's disease. In the neck, we look for cancers as well as other abnormalities."
"In the chest, abdomen, and pelvis, we not only look for vascular abnormalities but also for early signs of cancer and other abnormalities, including metabolic abnormalities within the liver. There is something called fatty liver disease, which is common in the US. So, the process involves a noninvasive MRI study with multiple different sequences looking at different areas within the body, and we put them all together in one visit."
#SimonMedImaging #MRI #WholeBodyScan #Diagnostics #AI #MedicalImaging #PreventativeMedicine